<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The objective of this study is to evaluate the prevalence of <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo>, mainly anti-beta(2)-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I (anti-beta(2)-GPI), and their possible clinical and laboratory relevance in <z:e sem="disease" ids="C0026272" disease_type="Disease or Syndrome" abbrv="MCTD">mixed connective tissue disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCTD</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>This study included 39 consecutive patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCTD</z:e> (Kasukawa's criteria) from January, 2005, to March, 2007, and compared them with 21 age- and sex-matched healthy controls </plain></SENT>
<SENT sid="2" pm="."><plain>IgG and IgM anticardiolipin (aCL) and anti-beta(2)-GPI were measured by ELISA </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">Lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> (LA) was detected by functional coagulation tests </plain></SENT>
<SENT sid="4" pm="."><plain>Medium to high titres of aCL and anti-beta(2)-GPI antibodies were found in sera from four (10.2%) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCTD</z:e> patients </plain></SENT>
<SENT sid="5" pm="."><plain>One of these patients was found to be positive for IgM aCL, IgM anti-beta(2)-GPI and LA antibodies simultaneously </plain></SENT>
<SENT sid="6" pm="."><plain>Additionally, this patient had a previous history of foetal loss in the second trimester and new-<z:hpo ids='HP_0003674'>onset</z:hpo> pulmonary arterial <z:hpo ids='HP_0000822'>hypertension</z:hpo> (<z:chebi fb="11" ids="104011,31204,33848,53305">PAH</z:chebi>) </plain></SENT>
<SENT sid="7" pm="."><plain>The other three patients had none of the manifestations of <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) or <z:chebi fb="11" ids="104011,31204,33848,53305">PAH</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>The mean value of IgG anti-beta(2)-GPI was higher among those <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCTD</z:e> patients with <z:chebi fb="11" ids="104011,31204,33848,53305">PAH</z:chebi> than in the group without <z:chebi fb="11" ids="104011,31204,33848,53305">PAH</z:chebi> (34.2 +/- 46.8 vs 12.3 +/- 9.1, P = 0.018) </plain></SENT>
<SENT sid="9" pm="."><plain>None of the controls were positive for <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>High to moderate titres of anti-beta(2)-GPI as well as APS were rare in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCTD</z:e>, and these antibodies may be correlated with the development of <z:chebi fb="11" ids="104011,31204,33848,53305">PAH</z:chebi> in these patients </plain></SENT>
</text></document>